







5 FEBRUARY 2021

LGP EXPORTS FIRST COMMERCIAL SHIPMENT OF CANNABIS FLOWER MEDICINES TO GERMANY

ASX ANNOUNCEMENT

Highlights:

-  LGP exports first commercial shipment of cannabis flower medicines to DEMECAN in Germany
-  Delivery of Shipment initiates three-year term of Purchase Agreement between LGP and DEMECAN
-  LGP joins a small group of international cannabis producers able to supply cannabis flower medicines into Germany
-  Company only the second producer to not require their cannabis flower medicines to be irradiated
-  Shipment continues the strong momentum LGP has seen in Europe following its recent success in the national French government tender
-  German medicinal cannabis market estimated to reach €7.7 billion by 2028

Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) is pleased to announce the dispatch and export of its first commercial shipment of cannabis flower medicines to Deutsche Medizinalcannabis GmbH (“DEMECAN”).

This initial shipment (“Shipment”) comprises 500 x 15g units of high-THC cannabis flower medicines and is due to arrive in Germany next week. On arrival in Germany, the Shipment will be batch-tested before being released to the German market. This milestone follows a rigorous 12-month audit and qualification process between the Company and DEMECAN’s quality and commercial teams to ensure compliance with all applicable EU and German regulatory requirements.



Commenting on the Shipment, LGP Managing Director Fleta Solomon said:

“Our partnership with DEMECAN represents a significant foundation on which to build LGP’s access to the German market. For the past year, we have worked closely with DEMECAN through a highly rigorous audit and qualification process, to ensure LGP’s cannabis flower medicines meet all applicable EU GMP and German quality requirements. In a particularly pleasing achievement, our cannabis flower medicines passed all microbiological testing without requiring irradiation; a testament to LGP’s ability to successfully cultivate and manufacture consistently high-quality cannabis flower medicines under indoor GACP and GMP conditions. We are very pleased with the final outcome and look forward to partnering with DEMECAN for many years to come.”

Following delivery of the Shipment, LGP joins a small group of international cannabis producers able to supply cannabis flower medicines into Germany and is only the second producer to not require their cannabis flower medicines to be irradiated. The Shipment delivery continues the strong momentum LGP has seen in Europe following its recent success in the national French government tender (see ASX announcement dated 27 January 2021).

The cannabis flower medicines are to be delivered pursuant to the medicinal cannabis purchase agreement between DEMECAN and LGP (see ASX announcement dated 27 February 2020) (“**Purchase Agreement**”). Under the Purchase Agreement LGP will sell and export to DEMECAN up to 1,000kg of LGP-cultivated dried cannabis flower or 48,000 units of LGP Classic medicinal cannabis oil product, or any combination thereof, per annum. The Purchase Agreement does not require DEMECAN to purchase a minimum volume and LGP does not consider the value of this initial shipment as being material.

The Agreement has a three-year term, which commences on delivery of the Shipment.

The cannabis flower used to produce the medicines was cultivated under Good Agricultural & Collection Practices (“**GACP**”) and manufactured in accordance with Good Manufacturing Practice (“**GMP**”) in LGP’s world-class indoor cultivation and manufacturing facility in South Western Australia. The Shipment represents the successful implementation of a second major product line for LGP, with the Company also planning to offer cannabis flower medicines to Australian prescribers and patients this calendar year.

German cannabis medicines market

The German medicinal cannabis market is the largest medicinal cannabis market in Europe and is anticipated to reach €7.7 billion (A\$12.22 billion) by 2028.¹ It is also a significant market for cannabis flower medicines, with flower sales representing ~21% of the market in Germany.²

¹ Prohibition Partners, *The Germany Cannabis Report*

² Prohibition Partners, *The European Cannabis Report 5 Ed.*





ENDS

BY ORDER OF THE BOARD

A handwritten signature in dark ink, appearing to read "Alistair Warren", is written over a horizontal line.

Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary

Little Green Pharma

E: alistair@lgpharma.com.au

M: +61 8 6280 0050

Fleta Solomon

Managing Director

Little Green Pharma

E: fleta@lgpharma.com.au

M: +41 782 260 200

About Little Green Pharma

Little Green Pharma is a vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has an indoor cultivation facility and manufacturing facility in Western Australia for the production of its own-branded range of GMP-grade medicinal cannabis products.

Little Green Pharma products comply with all required Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

